Individual results vary significantly between patients
While individual results can vary, Contrave is approved for chronic weight management in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with at least one weight-related comorbidity
18, May 2021, pp
ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
Check Out Our 5 Star Reviews Additional Services We Offer Medical Marijuana Medical Weight Loss Immigration Physical Workers Comp Internal Medicine Telemedicine Visits Ozempic Injection Vaccination IV Therapy Semaglutide GLP-1 Injections Vitamin B12 Shots Hormone Testing Joint Pain BHRT Additional Services We Offer Medical Marijuana Medical Weight Loss Immigration Physical Workers Comp Internal Medicine Telemedicine Visits Ozempic Injection Vaccination IV Therapy Semaglutide GLP-1 Injections Vitamin B12 Shots Hormone Testing Joint Pain BHRT
However, for patients with pre-existing gastrointestinal conditions such as gastroparesis (paralyzed stomach), severe gastroesophageal reflux disease (GERD), or inflammatory bowel disease (IBD), this mechanism can exacerbate symptoms
